# Mangoceuticals, Inc. (MGRX) · Edgar & Edgarette company card

> Mangoceuticals (MGRX) saw revenue fall 26.0% in FY2025 to $0 million, operating margin -3954% against a 2.0% median for misc health & allied services, equity 94.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1938046 · fiscal year ended 2025-12-31 · 4 audited years read · [page](https://www.pops4.com/boards/company/MGRX) · [JSON](https://www.pops4.com/boards/company/MGRX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $456,021 |
| Revenue growth, 1 year | -26.0% |
| Revenue growth per year | 270.8% |
| Operating margin | -3954.3% (prior year -1294.4%) |
| Net margin | -4526.9% |
| Operating cash flow | −$6M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $1M |
| Long-term debt | — |
| Total assets | $16M |
| Total equity | $15M |
| Equity ÷ assets | 94.5% |
| Return on equity | -135.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 2.42 (grey zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, late quarterly report notice in the last 12 months; operating cash flow was negative (-$5.9M in FY2025); operating loss: a margin of -3954.3% in FY2025; revenue is hard to predict: its 80% range is ±47%

## Edgarette's reading

Exposure: revenue $456K (FY2025). Experience: revenue down 26.0% on the year, up 270.8% a year over 3 years; operating margin -3954.3%, down from -1294.4%. Soundness: equity 94.5% of assets, return on equity -135.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $594K and $1.7M next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $554K to $1.8M. A statistical range, not company guidance. Against peers (54 filers, $50M+ revenue, its industry group): operating margin -3954.3% against a 2.0% median; growth -26.0% against 13.0%.

Range logged 2026-10-02, receipt 0d80ca6f1ce58f89, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-03-31 ([filing](https://www.sec.gov/Archives/edgar/data/1938046/000149315226014360/0001493152-26-014360-index.htm))
- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-02-06 ([filing](https://www.sec.gov/Archives/edgar/data/1938046/000149315226005587/0001493152-26-005587-index.htm))
- Item NT 10-Q Late quarterly report notice: 1, latest 2026-05-15 ([filing](https://www.sec.gov/Archives/edgar/data/1938046/000149315226023883/0001493152-26-023883-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-07-30 ([filing](https://www.sec.gov/Archives/edgar/data/1938046/000149315226035323/0001493152-26-035323-index.htm))

## Recent filings

- 8-K · filed 2026-11-13 · 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1938046/000149315226051858/0001493152-26-051858-index.htm)
- 8-K · filed 2026-11-06 · 5.07 Submission of Matters to a Vote of Security Holders; 5.08 Shareholder Nominations Pursuant to Rule 14a-11; 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1938046/000149315226050533/0001493152-26-050533-index.htm)
- 8-K · filed 2026-10-09 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1938046/000149315226046510/0001493152-26-046510-index.htm)
- 8-K · filed 2026-10-01 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1938046/000149315226045341/0001493152-26-045341-index.htm)
- 8-K · filed 2026-08-21 · 1.02 Termination of a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1938046/000149315226039724/0001493152-26-039724-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1938046/000149315226037873/0001493152-26-037873-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001938046.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1938046

## Cite

POPS4, Edgar & Edgarette: Mangoceuticals, Inc. (MGRX) company card, from the company's own SEC filings, accessed 2026-11-16, https://www.pops4.com/boards/company/MGRX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

